30 July 2019

Bart Kiemeny is on stage in his Radboudumc cycling outfit, 3500 kilometers in his legs and surrounded by podium girls of ‘Daags na de Tour’. Because yes, professor Bart Kiemeney cycled the Tour de France. For more money on cancer research.

With over €47,000 on the counter, Kiemeney can see the Tour de France as a great success. Not only did he get close to his target amount (you can still donate!), but Bart was also one of the few to have covered the entire course of this edition of the Tour de France.

 "Now I'm really not going to cycle the Tour anymore!” the professor writes in his epilogue.
 

Bart's Tour de France

Read the entire epilogue on www.tourdefrancevanbart.nl or donate.
That's still possible!

Related news items


Large AI project receives over €95 million for ten years of public-private research

23 September 2021

Radboud university medical center (Radboudumc) participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboud university medical center leads five of these eight labs.

read more

Reading ADP-ribosylation signaling using chemical biology and interaction proteomics published in Molecular Cell

22 September 2021

Kasia Kliza and Michiel Vermeulen worked on a project to synthesize biotinylated ADPr-based probes that can identify ADPr readers and determine their specificity for mono- and polyADPr. They published this in Molecular Cell.

read more

Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield

22 September 2021

Christian Gilissen and colleagues published in Genetics in Medicine about their work guiding the application of short tandem repeat analysis in clinical exome sequencing.

read more

TropIQ seeks new mosquito repellents

21 September 2021

TropIQ Health Sciences, a Radboudumc spin-off, has received a 1.3 million USD grant from the Bill & Melinda Gates Foundation to track down new mosquito repellents.

read more

New start-up Patholyt will bring AI research into pathology diagnostics

21 September 2021

Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.

read more

Treatment of most common skin cancer can sometimes wait

20 September 2021

Not treating but keeping an eye on the cancer is also an option

read more